Capstone Investment Advisors
CLSD

Capstone Investment Advisors’s Clearside Biomedical CLSD Stock Holding History

Capstone Investment Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-790
Closed -$71K – 1873
2021
Q3 		$71K Buy
+790
New +$69.7K ﹤0.01% 1818

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capstone Investment Advisors's CLSD Position: Q4 2021 in Review

Capstone Investment Advisors sold out of Clearside Biomedical (CLSD) in Q4 2021, closing a stake of 790 shares — an estimated $71K sold.

Capstone Investment Advisors first reported a position in CLSD in Q3 2021 and held it in 1 quarter. The position peaked at $71K in Q3 2021. 67 funds tracked by Wall St. Rank hold CLSD as of Q4 2021.

  • Capstone Investment Advisors reported no remaining Clearside Biomedical position as of Q4 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 790 Clearside Biomedical shares in Q4 2021, an estimated $71K.
  • Capstone Investment Advisors first reported a position in Clearside Biomedical in Q3 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Clearside Biomedical position peaked at $71K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2021.

Based on Capstone Investment Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.